Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Short-Term Debt issuances (2018 - 2020)

Organogenesis Holdings has reported Short-Term Debt issuances over the past 3 years, most recently at -$29.4 million for Q4 2020.

  • Quarterly results put Short-Term Debt issuances at -$29.4 million for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2021 was -$29.4 million (changed 0.0% YoY), and the annual figure for FY2021 was -$10.0 million, up 57.42%.
  • Short-Term Debt issuances for Q4 2020 was -$29.4 million at Organogenesis Holdings, down from $2.5 million in the prior quarter.
  • Over the last five years, Short-Term Debt issuances for ORGO hit a ceiling of $6.2 million in Q4 2018 and a floor of -$29.4 million in Q4 2020.
  • Median Short-Term Debt issuances over the past 3 years was $2.5 million (2019), compared with a mean of -$1.9 million.
  • Peak annual rise in Short-Term Debt issuances hit 46.34% in 2019, while the deepest fall reached 42.69% in 2019.
  • Organogenesis Holdings' Short-Term Debt issuances stood at $6.2 million in 2018, then plummeted by 60.0% to $2.5 million in 2019, then tumbled by 1274.12% to -$29.4 million in 2020.
  • The last three reported values for Short-Term Debt issuances were -$29.4 million (Q4 2020), $2.5 million (Q2 2019), and $4.5 million (Q1 2019) per Business Quant data.